Project Scope |
This Project team will create a White Paper with recommendations for Treatment Emergent Definitions, with a focus on Phase 2-4 clinical trials. This White Paper will build upon a White Paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices. |
Project Leads | Emails |
---|
Mary Nilsson (Eli Lilly)
William Palo |
, Abbvie |
Nicola Newton |
, PHUSE |
Project Assistant |
Objectives & Deliverables
Project team review final White Paper
|
---|
Working on a White Paper
Kirthi Rangaraju
Q3 2024 |
---|
|
Objectives & Deliverables | Timelines |
---|---|
White Paper - Recommended Definition of Treatment-Emergent Adverse Events in Clinical Trials' | Q3 2024 |